Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis

Parveen K. Garg; Neal W. Jorgensen; Robyn L. McClelland; Nancy S. Jenny; Michael H. Criqui; Matthew A. Allison; Philip Greenland; Robert S. Rosenson; David S. Siscovick; Mary Cushman

doi:10.1177/1358863X16671424

Lipoprotein-associated phospholipase A₂ and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis

Parveen K. Garg^*, Neal W. Jorgensen, Robyn L. McClelland, Nancy S. Jenny, Michael H. Criqui, Matthew A. Allison, Philip Greenland, Robert S. Rosenson, David S. Siscovick, Mary Cushman

^*Corresponding author for this work

Preventive Medicine

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Prospective studies supporting a relationship between elevated lipoprotein-associated phospholipase A₂ (Lp-PLA₂) and incident peripheral arterial disease (PAD) are limited. We evaluated the association of Lp-PLA₂ with incident PAD in a multi-ethnic cohort without clinical cardiovascular disease. A total of 4622 participants with measurement of Lp-PLA₂ mass and Lp-PLA₂ activity and an ankle-brachial index (ABI) between 0.9 and 1.4 were followed for the development of PAD (median follow-up = 9.3 years), defined as an ABI ≤0.9 and decline from baseline ≥0.15. There were 158 incident PAD events during follow-up. In adjusted logistic regression models, each higher standard deviation of both Lp-PLA₂ activity and mass did not confer an increased risk of developing PAD [odds ratios, (95% confidence intervals)]: 0.92 (0.66-1.27) for Lp-PLA₂ activity and 1.06 (0.85-1.34) for mass. Additionally, no significant interaction was found according to ethnicity: p=0.43 for Lp-PLA₂ activity and p=0.55 for Lp-PLA₂ mass. We found no evidence of an association between Lp-PLA₂ and incident PAD.

Original language	English (US)
Pages (from-to)	5-12
Number of pages	8
Journal	Vascular Medicine (United Kingdom)
Volume	22
Issue number	1
DOIs	https://doi.org/10.1177/1358863X16671424
State	Published - Feb 1 2017

Keywords

ankle-brachial index
inflammation
lipoprotein-associated phospholipase A
peripheral arterial disease (PAD)

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/1358863X16671424

Cite this

Garg, P. K., Jorgensen, N. W., McClelland, R. L., Jenny, N. S., Criqui, M. H., Allison, M. A., Greenland, P., Rosenson, R. S., Siscovick, D. S., & Cushman, M. (2017). Lipoprotein-associated phospholipase A₂ and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis. Vascular Medicine (United Kingdom), 22(1), 5-12. https://doi.org/10.1177/1358863X16671424

@article{05622c3dd4404217b47c295fc4290b8d,

title = "Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis",

abstract = "Prospective studies supporting a relationship between elevated lipoprotein-associated phospholipase A2 (Lp-PLA2) and incident peripheral arterial disease (PAD) are limited. We evaluated the association of Lp-PLA2 with incident PAD in a multi-ethnic cohort without clinical cardiovascular disease. A total of 4622 participants with measurement of Lp-PLA2 mass and Lp-PLA2 activity and an ankle-brachial index (ABI) between 0.9 and 1.4 were followed for the development of PAD (median follow-up = 9.3 years), defined as an ABI ≤0.9 and decline from baseline ≥0.15. There were 158 incident PAD events during follow-up. In adjusted logistic regression models, each higher standard deviation of both Lp-PLA2 activity and mass did not confer an increased risk of developing PAD [odds ratios, (95% confidence intervals)]: 0.92 (0.66-1.27) for Lp-PLA2 activity and 1.06 (0.85-1.34) for mass. Additionally, no significant interaction was found according to ethnicity: p=0.43 for Lp-PLA2 activity and p=0.55 for Lp-PLA2 mass. We found no evidence of an association between Lp-PLA2 and incident PAD.",

keywords = "ankle-brachial index, inflammation, lipoprotein-associated phospholipase A, peripheral arterial disease (PAD)",

author = "Garg, {Parveen K.} and Jorgensen, {Neal W.} and McClelland, {Robyn L.} and Jenny, {Nancy S.} and Criqui, {Michael H.} and Allison, {Matthew A.} and Philip Greenland and Rosenson, {Robert S.} and Siscovick, {David S.} and Mary Cushman",

note = "Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this research was supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040 and UL1-TR-001079 from the National Center for Research Resources. Additional support was from an investigator-initiated grant from GlaxoSmithKline. Dr Cushman and Dr Jenny have had other funding from Diadexus. The funding sources did not have a role in the design, analysis or approval of the manuscript. Publisher Copyright: {\textcopyright} The Author(s) 2016.",

year = "2017",

month = feb,

day = "1",

doi = "10.1177/1358863X16671424",

language = "English (US)",

volume = "22",

pages = "5--12",

journal = "Vascular Medicine (United Kingdom)",

issn = "1358-863X",

publisher = "SAGE Publications Ltd",

number = "1",

}

Garg, PK, Jorgensen, NW, McClelland, RL, Jenny, NS, Criqui, MH, Allison, MA, Greenland, P, Rosenson, RS, Siscovick, DS & Cushman, M 2017, 'Lipoprotein-associated phospholipase A₂ and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis', Vascular Medicine (United Kingdom), vol. 22, no. 1, pp. 5-12. https://doi.org/10.1177/1358863X16671424

Lipoprotein-associated phospholipase A₂ and risk of incident peripheral arterial disease in a multi-ethnic cohort: The Multi-Ethnic Study of Atherosclerosis. / Garg, Parveen K.; Jorgensen, Neal W.; McClelland, Robyn L. et al.
In: Vascular Medicine (United Kingdom), Vol. 22, No. 1, 01.02.2017, p. 5-12.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Lipoprotein-associated phospholipase A2 and risk of incident peripheral arterial disease in a multi-ethnic cohort

T2 - The Multi-Ethnic Study of Atherosclerosis

AU - Garg, Parveen K.

AU - Jorgensen, Neal W.

AU - McClelland, Robyn L.

AU - Jenny, Nancy S.

AU - Criqui, Michael H.

AU - Allison, Matthew A.

AU - Greenland, Philip

AU - Rosenson, Robert S.

AU - Siscovick, David S.

AU - Cushman, Mary

N1 - Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: this research was supported by contracts HHSN268201500003I, N01-HC-95159, N01-HC-95160, N01-HC-95161, N01-HC-95162, N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167, N01-HC-95168, and N01-HC-95169 from the National Heart, Lung, and Blood Institute, and by grants UL1-TR-000040 and UL1-TR-001079 from the National Center for Research Resources. Additional support was from an investigator-initiated grant from GlaxoSmithKline. Dr Cushman and Dr Jenny have had other funding from Diadexus. The funding sources did not have a role in the design, analysis or approval of the manuscript. Publisher Copyright: © The Author(s) 2016.

PY - 2017/2/1

Y1 - 2017/2/1

N2 - Prospective studies supporting a relationship between elevated lipoprotein-associated phospholipase A2 (Lp-PLA2) and incident peripheral arterial disease (PAD) are limited. We evaluated the association of Lp-PLA2 with incident PAD in a multi-ethnic cohort without clinical cardiovascular disease. A total of 4622 participants with measurement of Lp-PLA2 mass and Lp-PLA2 activity and an ankle-brachial index (ABI) between 0.9 and 1.4 were followed for the development of PAD (median follow-up = 9.3 years), defined as an ABI ≤0.9 and decline from baseline ≥0.15. There were 158 incident PAD events during follow-up. In adjusted logistic regression models, each higher standard deviation of both Lp-PLA2 activity and mass did not confer an increased risk of developing PAD [odds ratios, (95% confidence intervals)]: 0.92 (0.66-1.27) for Lp-PLA2 activity and 1.06 (0.85-1.34) for mass. Additionally, no significant interaction was found according to ethnicity: p=0.43 for Lp-PLA2 activity and p=0.55 for Lp-PLA2 mass. We found no evidence of an association between Lp-PLA2 and incident PAD.

AB - Prospective studies supporting a relationship between elevated lipoprotein-associated phospholipase A2 (Lp-PLA2) and incident peripheral arterial disease (PAD) are limited. We evaluated the association of Lp-PLA2 with incident PAD in a multi-ethnic cohort without clinical cardiovascular disease. A total of 4622 participants with measurement of Lp-PLA2 mass and Lp-PLA2 activity and an ankle-brachial index (ABI) between 0.9 and 1.4 were followed for the development of PAD (median follow-up = 9.3 years), defined as an ABI ≤0.9 and decline from baseline ≥0.15. There were 158 incident PAD events during follow-up. In adjusted logistic regression models, each higher standard deviation of both Lp-PLA2 activity and mass did not confer an increased risk of developing PAD [odds ratios, (95% confidence intervals)]: 0.92 (0.66-1.27) for Lp-PLA2 activity and 1.06 (0.85-1.34) for mass. Additionally, no significant interaction was found according to ethnicity: p=0.43 for Lp-PLA2 activity and p=0.55 for Lp-PLA2 mass. We found no evidence of an association between Lp-PLA2 and incident PAD.

KW - ankle-brachial index

KW - inflammation

KW - lipoprotein-associated phospholipase A

KW - peripheral arterial disease (PAD)

UR - http://www.scopus.com/inward/record.url?scp=85014496697&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014496697&partnerID=8YFLogxK

U2 - 10.1177/1358863X16671424

DO - 10.1177/1358863X16671424

M3 - Article

C2 - 28215109

AN - SCOPUS:85014496697

SN - 1358-863X

VL - 22

SP - 5

EP - 12

JO - Vascular Medicine (United Kingdom)

JF - Vascular Medicine (United Kingdom)

IS - 1

ER -